Startups
DalCor is a biopharmaceutical company with a focus on addressing cardiovascular disease, the greatest global healthcare burden. Our purpose is to deliver the first pharmacogenomic precision medicine in cardiovascular disease that specifically targets patients with the ADCY9 AA genotype. The company has operations in Canada, the UK, Switzerland, and the U.S.
dal-GenE Phase 3 Clinical Trial
DalCor is conducting dal-GenE (DAL-301), the first interventional precision medicine cardiovascular outcomes trial. This Phase 3 clinical trial is evaluating the efficacy of dalcetrapib versus placebo to reduce clinical cardiovascular events in 6,149 patients who have experienced an -Acute Coronary Syndrome (ACS) who carry the ADCY9 rs1967309 AA genotype. The trial aims to reduce major adverse cardiovascular events (MACE). The dal-GenE trial is fully recruited, passed a futility analysis in January 2020, and trial completion is expected in the first half of 2021.
dal-COVID Clinical Trial
Coronavirus disease 2019 (COVID-19) is defined as illness caused by a novel coronavirus now called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Pre-clinical research has identified that the main protease (3CLMpro) of the SARS-CoV-2 virus is a key enzyme that plays a pivotal role in mediating viral replication and transcription. Dalcetrapib is a potential anti-viral treatment as it binds to the catalytic site of 3CLMpro of SARS-CoV-2 in vitro, thereby inhibiting its activity and viral replication.
In December 2020, DalCor initiated the dal-COVID trial, a Phase 2 proof-of-concept study for dalcetrapib as a potential oral anti-viral treatment for COVID-19.
dal-COVID is a double-blind, placebo-controlled trial in patients with confirmed mild to moderate symptomatic COVID-19. The study will evaluate the efficacy and safety of three different doses of dalcetrapib compared to placebo in approximately 200 adult patients over a 10-day treatment period. Results are anticipated in Q1 2021
dal-GenE Phase 3 Clinical Trial
DalCor is conducting dal-GenE (DAL-301), the first interventional precision medicine cardiovascular outcomes trial. This Phase 3 clinical trial is evaluating the efficacy of dalcetrapib versus placebo to reduce clinical cardiovascular events in 6,149 patients who have experienced an -Acute Coronary Syndrome (ACS) who carry the ADCY9 rs1967309 AA genotype. The trial aims to reduce major adverse cardiovascular events (MACE). The dal-GenE trial is fully recruited, passed a futility analysis in January 2020, and trial completion is expected in the first half of 2021.
dal-COVID Clinical Trial
Coronavirus disease 2019 (COVID-19) is defined as illness caused by a novel coronavirus now called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Pre-clinical research has identified that the main protease (3CLMpro) of the SARS-CoV-2 virus is a key enzyme that plays a pivotal role in mediating viral replication and transcription. Dalcetrapib is a potential anti-viral treatment as it binds to the catalytic site of 3CLMpro of SARS-CoV-2 in vitro, thereby inhibiting its activity and viral replication.
In December 2020, DalCor initiated the dal-COVID trial, a Phase 2 proof-of-concept study for dalcetrapib as a potential oral anti-viral treatment for COVID-19.
dal-COVID is a double-blind, placebo-controlled trial in patients with confirmed mild to moderate symptomatic COVID-19. The study will evaluate the efficacy and safety of three different doses of dalcetrapib compared to placebo in approximately 200 adult patients over a 10-day treatment period. Results are anticipated in Q1 2021
Overview
Location
Canada, Montreal (06), Montreal
Employees
11-50
Total raised
$230M
Founded date
2015
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Apr 19, 2016 | Funding round | $150M |
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 19, 2016 | DalCor Pharmaceuticals Raises $150M in Financing | DalCor Pharmaceuticals, a developer of treatments for cardiovascular disease, raised $150m in financing. This included a $50m Series A financing round late in 2015 and a $100m Series B round this week. Lead investors include Sanderling Vent... |
| DalCor Pharmaceuticals | “DalCor is developing dalcetrapib, a precision pharmacogenetic medicine for patients with a heart attack to reduce the risk of recurrent myocardial infarction.” |
Reviews 0
FAQ about DalCor Pharmaceuticals
When was DalCor Pharmaceuticals founded?
DalCor Pharmaceuticals was founded in 2015.
How much funding has DalCor Pharmaceuticals raised?
DalCor Pharmaceuticals has raised $230M in total across 2 funding rounds.
What funding rounds has DalCor Pharmaceuticals raised?
Parsers VC lists 2 funding rounds of DalCor Pharmaceuticals, among them a funding round of $150M on Apr 19, 2016.
What has the press written about DalCor Pharmaceuticals?
Parsers VC has collected 3 articles mentioning DalCor Pharmaceuticals, among them “DalCor Pharmaceuticals Raises $150M in Financing” (Apr 19, 2016) and “DalCor Pharmaceuticals”.
Is DalCor Pharmaceuticals still active?
Yes, DalCor Pharmaceuticals is active; its latest activity on Parsers VC dates from Sep 21, 2023.